loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations
Open ICICI 3-in-1 Account

Nifty Healthcare Index Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Torrent Pharmaceuticals Ltd. 13 Feb 2026 17:42 PM
Result PDF

Q3FY26 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.

Pharmaceuticals company Torrent Pharmaceuticals announced Q3FY26 results

  • Total Income: Rs 3,303 crore against Rs 2,809 crore during Q3FY25, change 18%.
    • India: Rs 1798 crore against Rs 1581 crore during Q3FY25, change 14%.
    • United States: Rs 321 crore against Rs 271 crore during Q3FY25, change 18%.
    • Germany: Rs 304 crore against Rs 282 crore during Q3FY25, change 8%.
    • Brazil: Rs 371 crore against Rs 291 crore during Q3FY25, change 27%.
    • Others: Rs 509 crore against Rs 384 crore during Q3FY25, change 33%.
  • EBITDA: Rs 1,088 crore against Rs 914 crore during Q3FY25, change 19%.
  • EBITDA Margin: 33% for Q3FY26.
  • PAT: Rs 635 crore against Rs 503 crore during Q3FY25, change 26%.
  • PAT Margin: 19% for Q3FY26.

Result PDF

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q3FY26 results

  • Total Revenue from Operations was Rs 37,368 million, with YoY growth of 10.7%.
    • India sales were Rs 24,959 million, YoY growth of 5.5%.
    • International sales were Rs 12,157 million, with YoY growth of 26.6%.
  • Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs 8,280 million, resulting in an EBITDA margin of 22.2% vs 22.5% in Q3FY25. EBITDA grew by 9.0% YoY.
  • R&D expenses for Q3FY26 were Rs 1,390 million, or 3.7% of total revenue from operations, vs Rs 1,312 million in Q3FY25 at 3.9% of total revenue from operations.
  • Profit before tax (after exceptional item) was Rs 7,812 million, YoY growth of 6.9%.
  • Net Profit (after Non-Controlling interest) was Rs 6,360 million, YoY growth of 1.6%.
  • Exceptional item for the quarter includes the impact of Rs 528 million on a preliminary basis related to the notification by the Government of India regarding the four Labour Codes.
  • According to IQVIA (SSA) data, for Q3FY26:
    • The Company registered a growth of 9.8% YoY vs the Indian Pharmaceutical Market (IPM), which grew by 10.9%.
    • Acute segment reported growth of 8.6% vs IPM, which grew by 7.8%, 80 bps outperformance.
    • Chronic segment reported growth of 15.8% vs IP,M which grew by 15.6%, 18 bps outperformance.

Sandeep Singh, Managing Director, Alkem Laboratories, said: “This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment. With its significant presence in high-barrier markets, best-in-class R&D and manufacturing, and robust quality systems, Occlutech provides a strong lever for Alkem MedTech to expand into cardiovascular, along with orthopaedics. Medtech is a natural extension for Alkem. In the company years, along with Enzene Biosciences, our Biotech arm, we expect Alkem MedTech to become a meaningful growth pillar for the company.”

Vikas Gupta, CEO, Alkem, said: “In Q3, we delivered a stable performance in a dynamic operating environment, supported by strong fundamentals in our domestic business and consistent execution across our international businesses. We remain bullish on the growth opportunities in domestic as well as international business and are on track to deliver our full-year guidance. Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets.”

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q3FY26 results

Consolidated Financial Highlights:

  • Consolidated Net total Income up 7% at Rs 2,412.69 crore.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.15% in Q3FY26 as against @ 19.87% in Q3FY25.
  • Consolidated Net Profit at Rs 326.27 crore (after exceptional items) up 31%.
  • Exports Income up 13% at Rs 770.49 crore.

Standalone Financial Highlights:

  • Standalone Net total Income up 11% at Rs 1,863.00 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 26.09% in Q3FY26 as against @ 24.25% in Q3FY25.
  • Standalone Net Profit at Rs 303.45 crore (after exceptional items) up 13%.
  • Indian formulations income up 12% at Rs 984.00 crore.

Result PDF

Pharmaceuticals company Lupin announced Q3FY26 results

  • Gross Profit was Rs 52,224 million compared to Rs 38,970 million in Q3FY25, with a gross margin of 73.5%.
  • Personnel cost was 16.1% of sales at Rs 11,433 million compared to Rs 9,844 million in Q3FY25.
  • Manufacturing and other expenses were 27.3% of sales at Rs 19,366 million compared to Rs 16,959 million in Q3FY25.
  • Adjusted PBT at Rs 15,220 million at 21.4%, up 42.1% YoY from Rs 10,713 million in Q3FY25.
  • PBT (excluding exceptional items) is Rs 19,486 million at 27.4%.
  • We have provided net one-time exceptional items of Rs 4,266 million.
  • Investment in R&D for the quarter was Rs 5,352 million (7.5% of sales).

Nilesh Gupta, Managing Director, Lupin, said: “We are happy to deliver another quarter of strong growth led by our highest ever quarterly sales in the US and double-digit growth in India and all other regions. We are on track to deliver a strong close to FY26."

Result PDF

Pharmaceuticals company Abbott India announced Q3FY26 results

  • Revenue: Rs 1,724.04 crore against Rs 1,614.28 crore during Q3FY25, change 7%.
  • PBT: Rs 508.98 crore against Rs 487.59 crore during Q3FY25, change 4%.
  • PAT: Rs 375.96 crore against Rs 360.78 crore during Q3FY25, change 4%.
  • EPS: Rs 176.92 for Q3FY26.

Result PDF

Healthcare Facilities company Apollo Hospitals Enterprise announced Q3FY26 results

  • Revenue: Rs 64,774 million against Rs 55,269 million during Q3FY25, change 17%.
  • EBITDA: Rs 9,653 million against Rs 7,615 million during Q3FY25, change 27%.
  • EBITDA Margin: 14.9% for Q3FY26.
  • PBT: Rs 6,820 million against Rs 5,362 million during Q3FY25, change 27%.
  • PBT Margin: 10.5% for Q3FY26.
  • PAT: Rs 5,215 million against Rs 3,723 million during Q3FY25, change 40%.

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q3FY26 results

  • Revenue from Operations increased by 8.4% YoY to Rs 8,646 crore with growth in Europe and ARV.
  • US formulations revenue increased by 2.2% YoY to Rs 3,739 crore (USD 420 million).
  • Europe formulations revenue increased by 27.4% YoY to Rs 2,703 crore (EUR 261 million).
  • Growth Markets revenue remained flat YoY at Rs 865 crore (USD 97 million).
  • ARV revenue increased by 22.4% YoY to Rs 376 crore (USD 42 million).
  • EBITDA before R&D stood at Rs 2,163 crores with a margin of 25.0%.
  • EBITDA before Forex and Other Income stood at Rs 1,773 crore; EBITDA margin at 20.5%.
  • Research & Development (R&D, including depreciation) spend was Rs 409 crore, 4.7% of revenues.
  • Received final approval for 7 ANDAs from the USFDA (including 2 ANDAs previously tentatively approved, now receiving final approval).
  • Net Profit for the period stood at Rs 910 crore. (inclusive of one-time cost due to change in labour code of Rs 65 crore).
  • Strong net cash position as on 31-Dec-25 after appropriating cash for the acquisition of Khandelwal laboratories is at USD 251 million.
  • Free Cashflows of USD 118 million generated during the quarter • Basic & Diluted EPS stood at Rs 15.67 per share.

K. Nithyananda Reddy, Vice-Chairman & Managing Director, said: “Q3 reflected steady execution across Aurobindo’s core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the U.S. and Europe. Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability. As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term.”

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q3FY26 results

  • Revenue from operations at Rs 68,645 million, up 30 % over last year.
  • Research & Development (R&D) investments for the quarter stood at Rs 6,074 million (8.8 % of revenues).
  • EBITDA for the quarter was Rs 18,164 million, up 31% YoY. EBITDA margin for the quarter stood at 26.5 %, which is an improvement of 20 bps on a YoY basis.
  • Net Profit (Adjusted) for the quarter was Rs 11,109 million, up 9% YoY.
  • Capex (organic) for the quarter was Rs 4,637 million.

Sharvil Patel, Managing Director - Zydus Lifesciences, said: "Our robust performance in 3QFY26 across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A and business development strategy is translating into tangible results, laying a strong foundation for sustained value creation. Anchored in patient centricity, supported by unwavering compliance and an agile supply chain, we continue to deliver quality products globally. We remain focused on consistent execution and driving long-term shareholder value."

Result PDF

Healthcare Facilities company Max Healthcare Institute announced Q3FY26 results

  • Gross Revenue stood at Rs 2,608 crore for Q3FY26, a growth of 10% YoY.
  • Network Operating EBITDA stood at Rs 648 crore in Q3FY26, a growth of 4% YoY.
  • Operating Margin stood at 26.1% compared to 27.3% in Q3FY25 and 26.9% in Q2FY26.
  • Network PAT stood at Rs 344 crore, compared to Rs 316 crore in Q3FY25 and Rs 554 crore in Q2FY26, reflecting a growth of 9% YoY. PAT is after expense of Rs 55 crore towards two exceptional items i.e. impact of Code on Wages, 2019 and provision for stamp duty on the amalgamation of Crosslay Remedies Ltd (CRL) with Jaypee Healthcare Ltd (JHL).
  • Free Cash from Operations was Rs 281 crore in Q3FY26 compared with Rs 303 crore in Q3FY25 and Rs 291 crore in Q2FY26.
  • EBITDA per bed4 was Rs 71.3 lakh compared to Rs 73.0 lakh in Q3FY25 and Rs 73.4 lakh in Q2FY26.
  • Bed occupancy for the quarter was at 74%, with Occupied Bed Days (OBDs) up by 7% YoY.
  • ARPOB 5 for Q3FY26 stood at Rs 77.9k compared to Rs 75.9k in Q3FY25 and Rs 77.3k in Q2FY26.
  • Free treatment provided to 38,915 patients in OPD and 1,568 patients in IPD from the economically weaker sections by the Network Hospitals.
  • The Company executed a Share Purchase Agreement for staggered acquisition of 100% equity stake in Yerawada Properties Pvt. Ltd. (YPPL) for developing a ~450 beds hospital, on a land parcel in prime location in Pune.
  • 160 beds MSSH Mohali brownfield tower: 53 beds commissioned with current occupancy of 46 beds delivering an EBITDA margin of ~39%. Balance beds will be commissioned by February end.
  • 280 beds Nanavati Max brownfield tower: 63 beds commissioned with current occupancy of 45 beds delivering an EBITDA margin of ~31%. Balance beds to be commissioned by March end.
  • 400 beds Max Smart brownfield tower: expected commissioning by February end in a phased manner, upon receipt of regulatory approvals.
  • The Board approved the brownfield expansion of the existing MSSH Dwarka facility to include 260 additional beds, to be constructed by the partner, taking the overall capacity to 560 beds.

Abhay Soi, Chairman & Managing Director, Max Healthcare Institute, said: “We are privileged to have treated over 40K patients free of cost in this quarter. We also continued our steady performance this quarter with Revenue and PAT growth of 10% and 9%, respectively. More importantly, we have operationalised new brownfield beds at Nanavati Max and MSSH Mohali, which have demonstrated accretive margins already. We expect a significant ramp up in our capacity in Q4 and in FY27. Encouraging performance in existing network hospitals and new capacity additions has boosted our confidence to further pursue growth opportunities, including our entry into Pune.”

Result PDF

Pharmaceuticals company Mankind Pharma announced Q3FY26 results

  • Revenue: Rs 3,567 crore against Rs 3,199 crore during Q3FY25, change 12%.
  • EBITDA: Rs 816 crore against Rs 819 crore during Q3FY25, change 0%.
  • EBITDA Margin: 22.9% for Q3FY26.
  • PAT: Rs 414 crore against Rs 378 crore during Q3FY25, change 10%.
  • PAT Margin: 11.6% for Q3FY26.
  • Diluted EPS of Rs 9.9 up by 6.7% YoY (FV Re.1).

Rajeev Juneja, Vice Chairman & Managing Director, said: “Mankind’s revenue increased 11.5% YoY, with adj. EBITDA margins of 25.9%, primarily due to improvement in domestic pharma and BSV consolidation.

Mankind’s chronic share increased by 200 bps YoY to 39.3%, driven by strong growth of 16.7% in cardiac and 14.4% in anti-diabetes. Revenue from OTC grew by 5.2% in Q3FY26 vs -2.6% in Q2FY26. We expect growth to improve further.

BSV growth initiatives progressing well; Strong double-digit growth in Q3.

We remain confident of delivering long term sustainable growth anchored by four key pillars - steady base business, fast-growing specialty chronic, high-potential OTC business, and super specialty BSV portfolio.”

Result PDF

Trending News

M&M in Talks to Upgrade South Africa Plant for CKD Units to Counter Chinese Rivalry

According to media sources, Mahindra & Mahindra is reportedly in advanced discussions to expand and upgrade its South African manufacturing facility, potentially introducing completely knocked down (CKD) production to strengthen local assembly operations. 

Published on 16-Apr-2026 09:13

L&T Delivers 7th 700 MWe Steam Generator to NPCIL Ahead of Schedule for Nuclear Expansion

Larsen & Toubro (L&T) has dispatched its 7th 700 MWe steam generator to Nuclear Power Corporation of India (NPCIL), marking a key milestone in India’s fast-track nuclear expansion programme. 

Published on 16-Apr-2026 09:12

India to Invite Bids for ₹5,960Cr Small Modular Reactor; Target 100GW Nuclear Capacity by 2047

India plans to invite bids within 3–6 months for a 220 MWe Bharat Small Modular Reactor (BSMR-200), with an estimated cost of ₹5,960 crore (₹30 crore/MW) and a construction timeline of 60-72 months. 

Published on 16-Apr-2026 09:11

ICICI Lombard Q4 PAT Up 7.3% to ₹547 Cr; Premium Growth Hits 18.2% as Underwriting Improves

ICICI Lombard reported a healthy operating performance in Q4FY26, supported by strong premium growth and improved underwriting metrics. 

Published on 16-Apr-2026 09:10

EU to cut tariff-free steel quotas by 47% and double duties on excess imports

As per media sources, European Union reached a preliminary agreement to tighten steel import safeguards by reducing the tariff-free import quota to 18.3 million metric tonnes

Published on 16-Apr-2026 09:09

Brigade signs JDA for Gunjur land; integrated 39-acre township to yield ₹7,200 crore GDV

Brigade Enterprises has secured 8.63 land in Gunjur, East Bengaluru through a Joint Development Agreement. 

Published on 16-Apr-2026 09:08

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app